News & Events about Morphic Holding Inc.
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic(Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will...
Globe Newswire
2 months ago
First patient dosed in global study of oral 47 integrin inhibitorWALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced ...
Globe Newswire
2 months ago
WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Bruce Rogers, President of Morphic, will participate in a ...
Morphic Holding, Inc. (NASDAQ:MORF Get Rating) has received a consensus rating of Buy from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among ...
Globe Newswire
3 months ago
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved 47 inhibitor WALTHAM, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical ...